Dexamethasone intravitreal implant for macular edema following retinal vein occlusion

Christopher J. Brady, Julia A. Haller

Research output: Contribution to journalArticle

Abstract

Retinal vein occlusion is a major cause of vision loss worldwide, second only to diabetic retinopathy among retinal vascular disorders. A novel bioerodable corticosteroid implant composed of 0.7 mg dexamethasone designed for in-office injection has recently been approved for the treatment of macular edema resulting from retinal vein occlusion, a major mechanism for decreased vision in the condition. Following a single injection, subjects in the Phase III clinical trial achieved three lines of visual acuity improvement significantly faster than subjects who received sham injection. Following repeat injection 6 months later, subjects achieved similar gains with manageable levels of increased intraocular pressure and cataract development. The dexamethasone intravitreal implant is an important option in the management of macular edema following retinal vein occlusion.

Original languageEnglish (US)
Pages (from-to)17-27
Number of pages11
JournalExpert Review of Ophthalmology
Volume8
Issue number1
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Retinal Vein Occlusion
Macular Edema
Dexamethasone
Injections
Retinal Vessels
Phase III Clinical Trials
Diabetic Retinopathy
Intraocular Pressure
Cataract
Visual Acuity
Adrenal Cortex Hormones
Therapeutics

Keywords

  • branch retinal vein occlusion
  • central retinal vein occlusion
  • corticosteroids
  • intravitreal dexamethasone
  • macular edema
  • ozurdex

ASJC Scopus subject areas

  • Ophthalmology
  • Biomedical Engineering
  • Optometry

Cite this

Dexamethasone intravitreal implant for macular edema following retinal vein occlusion. / Brady, Christopher J.; Haller, Julia A.

In: Expert Review of Ophthalmology, Vol. 8, No. 1, 02.2013, p. 17-27.

Research output: Contribution to journalArticle

Brady, Christopher J. ; Haller, Julia A. / Dexamethasone intravitreal implant for macular edema following retinal vein occlusion. In: Expert Review of Ophthalmology. 2013 ; Vol. 8, No. 1. pp. 17-27.
@article{5a22473377cc4fa9acf39c6d9cefe659,
title = "Dexamethasone intravitreal implant for macular edema following retinal vein occlusion",
abstract = "Retinal vein occlusion is a major cause of vision loss worldwide, second only to diabetic retinopathy among retinal vascular disorders. A novel bioerodable corticosteroid implant composed of 0.7 mg dexamethasone designed for in-office injection has recently been approved for the treatment of macular edema resulting from retinal vein occlusion, a major mechanism for decreased vision in the condition. Following a single injection, subjects in the Phase III clinical trial achieved three lines of visual acuity improvement significantly faster than subjects who received sham injection. Following repeat injection 6 months later, subjects achieved similar gains with manageable levels of increased intraocular pressure and cataract development. The dexamethasone intravitreal implant is an important option in the management of macular edema following retinal vein occlusion.",
keywords = "branch retinal vein occlusion, central retinal vein occlusion, corticosteroids, intravitreal dexamethasone, macular edema, ozurdex",
author = "Brady, {Christopher J.} and Haller, {Julia A.}",
year = "2013",
month = "2",
doi = "10.1586/eop.12.69",
language = "English (US)",
volume = "8",
pages = "17--27",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Dexamethasone intravitreal implant for macular edema following retinal vein occlusion

AU - Brady, Christopher J.

AU - Haller, Julia A.

PY - 2013/2

Y1 - 2013/2

N2 - Retinal vein occlusion is a major cause of vision loss worldwide, second only to diabetic retinopathy among retinal vascular disorders. A novel bioerodable corticosteroid implant composed of 0.7 mg dexamethasone designed for in-office injection has recently been approved for the treatment of macular edema resulting from retinal vein occlusion, a major mechanism for decreased vision in the condition. Following a single injection, subjects in the Phase III clinical trial achieved three lines of visual acuity improvement significantly faster than subjects who received sham injection. Following repeat injection 6 months later, subjects achieved similar gains with manageable levels of increased intraocular pressure and cataract development. The dexamethasone intravitreal implant is an important option in the management of macular edema following retinal vein occlusion.

AB - Retinal vein occlusion is a major cause of vision loss worldwide, second only to diabetic retinopathy among retinal vascular disorders. A novel bioerodable corticosteroid implant composed of 0.7 mg dexamethasone designed for in-office injection has recently been approved for the treatment of macular edema resulting from retinal vein occlusion, a major mechanism for decreased vision in the condition. Following a single injection, subjects in the Phase III clinical trial achieved three lines of visual acuity improvement significantly faster than subjects who received sham injection. Following repeat injection 6 months later, subjects achieved similar gains with manageable levels of increased intraocular pressure and cataract development. The dexamethasone intravitreal implant is an important option in the management of macular edema following retinal vein occlusion.

KW - branch retinal vein occlusion

KW - central retinal vein occlusion

KW - corticosteroids

KW - intravitreal dexamethasone

KW - macular edema

KW - ozurdex

UR - http://www.scopus.com/inward/record.url?scp=84873396560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873396560&partnerID=8YFLogxK

U2 - 10.1586/eop.12.69

DO - 10.1586/eop.12.69

M3 - Article

AN - SCOPUS:84873396560

VL - 8

SP - 17

EP - 27

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 1

ER -